Selective Progesterone Receptor Modulator Demonstrates Efficacy in Treating Premenstrual Dysphoric Disorder

Summary

A randomized clinical trial shows the selective progesterone receptor modulator vilaprisan significantly reduces symptoms of PMDD compared to placebo. This represents a critical shift toward targeted hormonal treatments for a severe psychiatric condition traditionally managed with antidepressants.

The finding updates the evidence base in Therapeutics and Care Delivery and is worth reading against prior studies on the same endpoint. Clinical-stage and evidence-dependent operators in the lane feel these prints first.

Sources

• OVUM Primary source